Opioid use disorder: Difference between revisions

From IDWiki
()
()
Line 37: Line 37:
   
 
*Management of opioid use disorders: a national clinical practice guideline. ''CMAJ''. 2018;190(9):e247-e257. doi: [https://doi.org/10.1503/cmaj.170958 10.1503/cmaj.170958]
 
*Management of opioid use disorders: a national clinical practice guideline. ''CMAJ''. 2018;190(9):e247-e257. doi: [https://doi.org/10.1503/cmaj.170958 10.1503/cmaj.170958]
  +
*Opioid Agonist Therapy:A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. 2021. Available at: https://www.camh.ca/-/media/files/professionals/canadian-opioid-use-disorder-guideline2021-pdf.pdf
   
 
[[Category:Addiction medicine]]
 
[[Category:Addiction medicine]]

Revision as of 10:59, 22 May 2021

Background

Epidemiology

  • The risk of OUD among patients treated with opioids for chronic pain is around 8 to 30%

Management

  • Precipitated withdrawal more dangerous than natural withdrawal

Acute Overdose

  • First give boluses of naloxone 0.04mg to 0.08mg IV to improve respiratory depression escalated quickly q2-3 minutes up to 0.4, 2, 4, 10, 15mg (start low and go fast)
  • Then start infusion of 2/3 the effective dose per hour
  • QRS and QT lengthening by blocking Na and K channels
    • May need repeated defibrillation, overdrive pacing, or ECMO

Opioid Substitution Therapy (OST)

Prevention

  • Follow safe prescribing practices
  • Risk assessment
    • Consider their personal and family history of psychiatric illness and substance use disorder
    • Consider their social history, including their living situation, safety of housing, personal safety, children or dependents, and social supports
    • Can use tools such as the opioid risk tool or SOAPP-R as a more formal risk assessment
    • Physical exam, looking for signs of substance use and its complications
    • Bloodwork, including liver function tests, hemoglobin, and MCV

Further Reading